1. Yao J.C., Hassan M., Phan A. et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063-72.
2. Kvols L.K. Metastatic carcinoid tumors and the malignant carcinoid syndrome. Ann N Y Acad Sci 1994;733:464-70.
3. Eriksson B., Kloppel G., Krenning E. et al. Consensus guidelines for the management of patients with digestive neuroendocrine tumors - welldifferentiated jejuna-ileal tumor/carcinoma. Neuroendocrinology 2008;87:8-19.
4. Ruszniewski P., Ish-Shalom S., Wymenga M. et al. Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology 2004;80(4):244-51.
5. Rinke A., Muller H.H., Schade-Brittinger C. et al. PROMID Study Group. Placebocontrolled, doubleblind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009;27(28):4656- 63. DOI: 10.1200/JCO.2009.22.8510.
6. Caplin M.E., Pavel M., Cwikla J.B. et al. CLARINET Investigators. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 2014;371(3):224-33. DOI: 10.1056/NEJMoa1316158.
7. Martin-Richard M., Massuti B., Pineda E. et al. TTD (Tumores del Tracto Digestivo) Study Group. Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study. BMC Cancer 2013;13:427. DOI: 10.1186/1471-2407-13-427.
8. Jann H., Denecke T., Koch M. et al. Impact of octreotide long- acting release on tumour growth control as a first-line treatment in neuroendocrine tumours of pancreatic origin. Neuroendocrinology 2013;98(2):137-43. DOI: 10.1159/000353785.
9. Oberg K. Interferon-alpha versus somatostatin or the combination of both in gastroenteropancreatic tumours. Digestion 1996;57 Suppl 1:81-3.
10. Raymond E., Dahan L., Raoul J.L. et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364(6):501-13. DOI: 10.1056/NEJMoa1003825.
11. Yao J.C., Shah M.H., Ito T. et al. RAD001 in Advanced neuroendocrine Tumors, 3rd Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364(6):514-23. DOI: 10.1056/NEJMoa1009290.
12. Panzuto F., Rinzivillo M., Fazio N. et al. Real-world study of everolimus in advanced progressive neuroendocrine tumors. Oncologist 2014;19(9):966-74. DOI: 10.1634/theoncologist.2014-0037.
13. Kamp K., Gumz B., Feelders R.A. et al. Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177) Lu-octreotate. Endocr Relat Cancer 2013;20(6):825-31. DOI: 10.1530/ERC- 13- 0254.
14. Hadoux J., Malka D., Planchard D. et al. Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma. Endocr Relat Cancer 2015;22(3):289-98. DOI: 10.1530/ERC- 15-0075.
15. Welin S., Sorbye H., Sebjornsen S. et al. Clinical effect of Temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer 2011;117(20):4617-22. DOI: 10.1002/cncr.26124.
16. Moertel C.G., Kvols L.K., O’Connell M.J., Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991;68(2):227-32.
17. Bajetta B., Rimassa L., Carnaghi C. et al. 5-fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors. Cancer 1998;83:372-8.
18. Ekeblad S., (http://www.ncbi.nlm.nih.gov/pubmed? term=Ekeblad%20S%5BAuthor%5D&cauthor=true&cauthor_uid=17505000) Sundin A., (http://www.ncbi.nlm.nih.gov/pubmed?term=Sundin%20A%5BAuthor%5D&cauthor=true&cauthor_uid=17505000) Janson E.T. et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. (http://www.ncbi.nlm.nih.gov/pubmed? term=Janson%20ET%5BAuthor%5D&cauthor=true&cauthor_uid=17505000) Clin Cancer (http://www.ncbi.nlm.nih.gov/pubmed/17505000)Res 2007;13:2986-91. (http://www.ncbi.nlm.nih.gov/pubmed/17505000)
19. (http://www.ncbi.nlm.nih.gov/pubmed/17505000) Bajetta E., (http://www.ncbi.nlm.nih.gov/pubmed?term=Bajetta%20E%5BAuthor%5D&cauthor=true&c author_uid=16937105) Catena L., (http://www.ncbi.nlm.nih.gov/pubmed? term=Catena%20L%5BAuthor%5D&cauthor=true&cauthor_uid=16937105) Procopio G. et al. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? (http://www.ncbi.nlm.nih.gov/pubmed? term=Procopio%20G%5BAuthor%5D&cauthor=true&cauthor_uid=16937105)Cancer Chemother Pharmacol 2007;59:637-42. (http://www.ncbi.nlm.nih.gov/pubmed/16937105)
20. (http://www.ncbi.nlm.nih.gov/pubmed/16937105) CassierP.A., (http://www.ncbi.nlm.nih.gov/pubmed? term=Cassier%20PA%5BAuthor%5D&cauthor=true&cauthor_uid=19472402) Walter T., (http://www.ncbi.nlm.nih.gov/pubmed? term=Walter%20T%5BAuthor%5D&cauthor=true&cauthor_uid=19472402) Eymard B. et al. Gemcitabine and oxaliplatin combination chemotherapy for metastatic well-differentiated neuroendocrine carcinomas: a single- center experience. Cancer 2009;115:3392-9. (http://www.ncbi.nlm.nih.gov/pubmed? term=Eymard%20B%5BAuthor%5D&cauthor=true&cauthor_uid=19472402)
21. Wells S.A., Asa S.L., Dralle H. et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. The American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma. Thyroid 2015;25(6):567-610. (http://www.ncbi.nlm.nih.gov/pubmed? term=Eymard%20B%5BAuthor%5D&cauthor=true&cauthor_uid=19472402)